# OnCo record pd-l1-ihc-28-8-pharmdx (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pd-l1-ihc-28-8-pharmdx/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "pd-l1-ihc-28-8-pharmdx" ;
  schema:name "PD-L1 IHC 28-8 pharmDx"@en ;
  schema:description "The PD-L1 stain paired with nivolumab: tumour-cell staining of 1% or more for nivolumab with ipilimumab in lung cancer, and a combined positive score of 1 or more in oesophageal and gastric cancers."@en ;
  schema:url <https://onco.cc/drugs/pd-l1-ihc-28-8-pharmdx/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150025>, <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools> ;
  onco:status "approved" ;
  onco:tag "test" ;
  onco:modality "PD-L1 immunohistochemistry companion diagnostic assay" ;
  schema:alternateName "PD-L1 IHC 28-8 pharmDx" ;
  onco:approval "US 2015: PD-L1 detection in non-squamous NSCLC (original PMA)", "US 2020: Companion diagnostic for nivolumab with ipilimumab in NSCLC (tumour-cell staining 1% or more)", "US 2026: Companion diagnostic for nivolumab in oesophageal squamous cell carcinoma and gastric, GEJ and oesophageal adenocarcinoma (CPS 1 or more)" ;
  onco:related <https://onco.cc/drugs/dako-pd-l1-22c3-pharmdx/>, <https://onco.cc/biomarkers/pd-l1-cps/>, <https://onco.cc/biomarkers/pd-l1-tc-score/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/>, <https://onco.cc/cancers/oesophageal-adenocarcinoma/>, <https://onco.cc/cancers/gastric/> ;
  onco:technologies <https://onco.cc/technologies/companion-diagnostic/>, <https://onco.cc/technologies/histopathology-ihc/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:companies <https://onco.cc/companies/agilent/> ;
  onco:terms <https://onco.cc/terms/pd-l1-testing/>, <https://onco.cc/terms/cps/>, <https://onco.cc/terms/tps/>, <https://onco.cc/terms/ihc/> .